Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation

Thumbnail Image
Date
2019-02-01
Authors
Peyrou, Mathieu
Giraudel, Jerome
Danhof, Meindert
Rigel, Dean F.
Major Professor
Advisor
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier B.V.
Authors
Research Projects
Organizational Units
Journal Issue
Is Version Of
Versions
Series
Department
Biomedical SciencesVeterinary Diagnostic and Production Animal Medicine
Abstract
Simultaneous blockade of angiotensin receptors and enhancement of natriuretic peptides (NP) by the first-in-class angiotensin receptor neprilysin (NEP) inhibitor sacubitril/valsartan constitutes an effective approach to treating heart failure. This study examined the effects of sacubitril/valsartan (225 and 675 mg/day) vs. placebo, sacubitril (360 mg/day), valsartan (900 mg/day), and benazepril (5 mg/day) on the dynamics of the renin-angiotensin-aldosterone system (RAAS) and the NP system in dogs. Beagle dogs (n = 18) were fed a low-salt diet (0.05% Na) for 15 days to model RAAS activation observed in clinical heart failure. Drugs were administered once daily during the last 10 days, while the effects on the RAAS and NPs were assessed on Day 1, 5, and 10. Steady-state pharmacokinetics of the test agents were evaluated on Day 5. Compared with placebo, sacubitril/valsartan (675 mg) substantially increased cGMP circulating levels, while benazepril and valsartan showed no effect. Additionally, sacubitril/valsartan (675 mg) and valsartan significantly increased plasma renin activity, angiotensin I and angiotensin II concentrations. Finally, sacubitril/valsartan (both doses), and valsartan significantly decreased plasma aldosterone vs. placebo. Systemic exposure to valsartan following sacubitril/valsartan 675 mg administration was similar to that observed with valsartan 900 mg administration alone. Sacubitril/valsartan favorably modulates the dynamics of the renin and NP cascades through complementary NEP and RAAS inhibition.
Comments
This is a manuscript of an article published as Mochel, Jonathan P., Chi Hse Teng, Mathieu Peyrou, Jerome Giraudel, Meindert Danhof, and Dean F. Rigel. "Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation." European Journal of Pharmaceutical Sciences 128 (2019): 103-111. DOI: 10.1016/j.ejps.2018.11.037. Copyright 2018 Elsevier. Posted with permission.
Description
Keywords
Citation
DOI
Copyright
Collections